Trial title not recorded
Diabetic Kidney Disease
Enrolment: 1323 · Results not recorded
Loading the evidence…
Drug · Semi-synthetic oleanane triterpenoid; ChEMBL holds three direct-interaction mechanisms, all disease-efficacy true: Keap1/Nrf2 inhibition (the mechanism invoked in the trauma literature, releasing NRF2 for antioxidant response element transcription), IKK-beta inhibition and PPAR-gamma antagonism. Max phase 3, never approved; the phase 3 BEACON diabetic CKD programme was terminated for excess heart-failure events and the Japanese AYAME phase 3 (NCT03550443) was also terminated. Trials retained from 35 matches spanning oncology, diabetic kidney disease, Alport syndrome and phase 1 pharmacology.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Diabetic Kidney Disease
Enrolment: 1323 · Results not recorded
Alport Syndrome
Enrolment: 187 · Results not recorded
End-Stage Renal Disease · Type 2 Diabetes
Enrolment: 0 · Results not recorded
Malignant Melanoma
Enrolment: 0 · Results not recorded
Solid Tumours · Lymphoid Malignancies
Enrolment: 21 · Results not recorded
Chronic Kidney Disease · Type 2 Diabetes
Enrolment: 18 · Results not recorded
Obesity
Enrolment: 22 · Results not recorded
Healthy Volunteers
Enrolment: 16 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Crush syndrome induced by 6 h of direct compression of both hind limbs with 3.6 kg blocks per side, followed by 3 or 24 h decompression
Bardoxolone methyl reduced renal KIM-1, NGAL, TNF-alpha, TGF-beta1 and total oxidant status and increased total antioxidant status at 3 and 24 h after decompression, lowered serum creatine kinase, blood urea nitrogen and creatinine, and decreased apoptosis.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.